Abstract
Stem-like CD8(+) T cells (T(SL)) are a subset of immune cells with superior persistence and antitumor immunity. They are TCF1(+) PD-1(+) and important for the expansion of tumor specific CD8(+) T cells in response to checkpoint blockade immunotherapy. In acute infections, naïve CD8(+) T cells differentiate into effector and memory CD8(+) T cells; in cancer and chronic infections, persistent antigen stimulation can lead to T cell exhaustion. Recent studies have highlighted the dichotomy between late dysfunctional (or exhausted) T cells (T(LD)) that are TCF1(-) PD-1(+) and self-renewing TCF1(+) PD-1(+) T(SL) from which they derive. TCF1(+) T(SL) cells are considered to have stem cell-like properties akin to memory T cell populations and can give rise to cytotoxic effector and transitory T cell phenotypes (T(TE)) which mediate tumor control. In this review, we will discuss recent advances made in research on the formation and expansion of T(SL), as well as distinct niches required for their differentiation and maintenance in the setting of cancer. We will also discuss potential strategies to generate these cells, with clinical implications for stemness enhancement in vaccine design, immune checkpoint blockade (ICB), and adoptive T cell therapies.